Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06914557 · ClinicalTrials.gov registry record · Phase 2

Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.

A Phase 2 study of Pain and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Fox Chase Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT06914557: Recruiting Phase 2 study of Pain and CIPN - Chemotherapy-Induced Peripheral Neuropathy, sponsored by Fox Chase Cancer Center.

NCT06914557 is a Phase 2 study of Pain and CIPN - Chemotherapy-Induced Peripheral Neuropathy that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 50 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06914557, a Phase 2 study of Pain and CIPN - Chemotherapy-Induced Peripheral Neuropathy, is actively recruiting participants, sponsored by Fox Chase Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form. In addition, the investigators will further assess pain using the EORTC CIPN-20 and determine whether Scrambler therapy results in improved levels of function as measured with the PDQ, and a decreased need for opioid medications. Our primary objective is to investigate whether Scrambler therapy with duloxetine is superior to duloxetine-based usual care in achieving at least a 50% reduction in pain scores, when comparing the cross-sectionally measured "average" pain score at day 35 to the cross-sectionally measured "average" pain score at baseline.

Primary Outcome

Investigate whether Scrambler therapy with duloxetine is superior to duloxetine alone in patient achievement of at least a 50% reduction in pain scores when comparing the cross-sectionally measured "average" pain score at day 35 to the cross-sectionally measured "average" pain score at baseline (baseline = day 1).

Interventions

  • DEVICE Scrambler Therapy
  • OTHER Questionnaire and Physical Exam

Study Locations (1)

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-03-03
Est. Completion 2027-06-30
Phase Phase 2
Fox Chase Cancer Center

183 total trials

What NCT06914557 shows while recruiting

NCT06914557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (84% lower).

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Scrambler Therapy is the first listed.

NCT06914557 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06914557 about?

NCT06914557 is a clinical study titled "Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy.". The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form. In addition, the investigators will further assess pain using the EORTC CIPN-20 and determine whether Scrambler...

What is the current status of trial NCT06914557?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-03-03. Estimated completion is 2027-06-30.

What conditions does trial NCT06914557 study?

This clinical trial studies the following conditions: Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy.

What interventions are being tested in trial NCT06914557?

The interventions under investigation include: Scrambler Therapy (DEVICE), Questionnaire and Physical Exam (OTHER).

Who is sponsoring clinical trial NCT06914557?

This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06914557 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06914557's enrollment target sits among peer trials

50 254th of 374 higher than 111 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06914557, the US trial registry maintained by the National Library of Medicine. NCT06914557 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.